[go: up one dir, main page]

RU93005089A - Производное белка с человека, днк, клетка, фармацевтическая композиция, применение производного белка с, способ получения - Google Patents

Производное белка с человека, днк, клетка, фармацевтическая композиция, применение производного белка с, способ получения

Info

Publication number
RU93005089A
RU93005089A RU93005089/13A RU93005089A RU93005089A RU 93005089 A RU93005089 A RU 93005089A RU 93005089/13 A RU93005089/13 A RU 93005089/13A RU 93005089 A RU93005089 A RU 93005089A RU 93005089 A RU93005089 A RU 93005089A
Authority
RU
Russia
Prior art keywords
protein
dna
obtaining
cell
pharmaceutical composition
Prior art date
Application number
RU93005089/13A
Other languages
English (en)
Other versions
RU2122004C1 (ru
Inventor
Эдвард Герлитз Брюс
Уильям Гриннелл Брайен
Original Assignee
Ели Лилли энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ели Лилли энд Компани filed Critical Ели Лилли энд Компани
Publication of RU93005089A publication Critical patent/RU93005089A/ru
Application granted granted Critical
Publication of RU2122004C1 publication Critical patent/RU2122004C1/ru

Links

Claims (1)

  1. Изобретение относится к производным человеческого протеина С с высокой активностью и сниженной зависимостью от тромбиновой активации. Эти производные отличаются от природных форм человеческого протеина с повышенной степенью активации, функциональной активностью и углеводородными структурами. Приведены ДНК соединения, векторы переноса, векторы экспрессии и трансформанты, применимые для получения этих производных.
RU93005089A 1992-05-21 1993-05-19 Производное белка с человека и фармацевтическая композиция, обладающая антитромбическим действием RU2122004C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21
US07/887,191 1992-05-21
US07/887.191 1992-05-21

Publications (2)

Publication Number Publication Date
RU93005089A true RU93005089A (ru) 1996-03-10
RU2122004C1 RU2122004C1 (ru) 1998-11-20

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93005089A RU2122004C1 (ru) 1992-05-21 1993-05-19 Производное белка с человека и фармацевтическая композиция, обладающая антитромбическим действием

Country Status (23)

Country Link
US (1) US5453373A (ru)
EP (1) EP0575054B1 (ru)
JP (1) JP3564150B2 (ru)
KR (1) KR100291529B1 (ru)
CN (1) CN1080658A (ru)
AT (1) ATE286121T1 (ru)
AU (1) AU661901B2 (ru)
BR (1) BR9301944A (ru)
CA (1) CA2096604C (ru)
CZ (1) CZ286016B6 (ru)
DE (1) DE69333727T2 (ru)
DK (1) DK0575054T3 (ru)
ES (1) ES2233925T3 (ru)
FI (1) FI932282A7 (ru)
HU (1) HU218408B (ru)
IL (1) IL105757A0 (ru)
MX (1) MX9302917A (ru)
MY (1) MY110664A (ru)
NO (1) NO311299B1 (ru)
NZ (1) NZ247651A (ru)
PH (1) PH29911A (ru)
PT (1) PT575054E (ru)
RU (1) RU2122004C1 (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993007491A1 (en) * 1991-10-04 1993-04-15 Board Of Regents Of The University Of Nebraska A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CO4950523A1 (es) 1997-04-28 2000-09-01 Lilly Co Eli Formulaciones de proteina c activada
BR9809932A (pt) * 1997-06-05 2000-08-01 Lilly Co Eli Métodos para tratamento de distúrbios trombóticos
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
WO2000006179A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company Cryogranulation of activated protein c
CA2347250A1 (en) 1998-10-22 2000-04-27 Sau-Chi Betty Yan Methods for treating sepsis
IL142255A0 (en) 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
CA2351470A1 (en) 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
DK1133314T3 (da) 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
ATE286122T1 (de) * 2000-02-02 2005-01-15 Lilly Co Eli Protein c derivate
CA2400187A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
BR0114771A (pt) * 2000-10-18 2004-07-27 Maxygen Aps Moléculas de proteìna c ou semelhantes a proteìna c ativada
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
KR20130140221A (ko) * 2005-04-13 2013-12-23 아스트라제네카 아베 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포
EP1913155A4 (en) * 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF RESULT IN SERIOUSLY SICK SUBJECTS
AU2008265770A1 (en) * 2007-06-18 2008-12-24 Oregon Health & Science University Protein C for use in maintaining hemostasis
EP2242875A4 (en) * 2008-01-15 2012-04-04 Univ British Columbia PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND
WO2010070137A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2015246656B2 (en) 2014-04-16 2020-06-18 Zz Biotech Llc Use of APC analogue for wound healing
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1637807A1 (ru) * 1984-04-10 1991-03-30 Полтавский медицинский стоматологический институт Средство дл индивидуальной профилактики венерических заболеваний у мужчин
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C

Similar Documents

Publication Publication Date Title
RU93005089A (ru) Производное белка с человека, днк, клетка, фармацевтическая композиция, применение производного белка с, способ получения
FI891980A7 (fi) Menetelmä terapeuttisesti aktiivisten N1-(1,2-cis-2-halogeenisyklopropyyli)substituoitujen pyridonikarboksyylihappojohdannaisten valmistamiseksi
NO882732L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
FR2629825B1 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
NO870240D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno-1,4-diazepiner.
ATA285187A (de) Substituierte alpha-aminosaeuren, ihre herstellung und diese enthaltende arzneimittel
NO880182L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,2-dihydro-3h-indazol-3-on-derivater.
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
CA2114313A1 (en) Bpc peptides, their preparation and use
IT8647666A0 (it) Peptidi e derivati peptidici, loro preparazione e loro impiego come medicamenti
NO871295D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
NO165071C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7-(3-amino-1-pyrrolidinyl)-8-klor-1-cyklopropyl-6- fluor-1,4,-dihydro-4-okso-3-kinolin-karboksylsyre.
NO166326C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive 3,7-substituerte-8-oxo-5-thia-1-azabicyclo-(4,2,0)oct-2-en-2-carboxylater.
ATE110742T1 (de) Peptid-verbindungen.
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
FI892684L (fi) Menetelmä terapeuttisesti aktiivisten 4-okso-imidatso/1,5-a/kinoksaliinijohdannaisten valmistamiseksi
FI890699L (fi) Renin inhiberande aminosyraderivat.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
ATE90359T1 (de) Peptide.
DE68907392D1 (de) Dysmnesie modifizierende arzneimittel.
IT8819791A0 (it) Peptidi ad attivita' farmaceutica.
NO166280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n,n'-disubstituerte ureaer.
IT8748235A0 (it) Peptidi e derivati peptidici, loro preparazione e loro impiego come medicamenti